Author | Araujo, Abelardo | |
Author | Martin, Fabiola | |
Access date | 2022-01-24T13:39:32Z | |
Available date | 2022-01-24T13:39:32Z | |
Document date | 2021 | |
Citation | ARAUJO, Abelardo; MARTIN, Fabiola. SARS-CoV-2 vaccination of people living with human T leukaemia virus type 1. Sexually Transmitted Infections, v. 0, p. 1, 2021. | pt_BR |
ISSN | 0148-5717 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/50855 | |
Language | eng | pt_BR |
Publisher | BMJ | pt_BR |
Rights | open access | pt_BR |
Title | SARS-CoV-2 vaccination of people living with human T leukaemia virus type 1 | pt_BR |
Type | Article | pt_BR |
DOI | 10.1136/sextrans-2021-055007 | |
Abstract | Several SARS-CoV-2 vaccines are being rolled out worldwide, following testing in healthy volunteers and smaller groups of people with comorbidities, including HIV. Human T-cell leukaemia virus type 1 (HTLV-1), a retrovirus like HIV, is oncogenic and can cause chronic immune dysfunction. However, there is no established antiretroviral treatment for HTLV-1. An estimated 10 million individuals live with HTLV-1 worldwide. Two main disease patterns are recognised: lymphoproliferative immunodeficient (adult T-cell leukaemia/lymphoma) and inflammatory immunodysfunctional (HTLV-1-associated myelopathy). | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | University of Queensland. School of Public Health. Brisbane, Queensland, Australia. | pt_BR |
Subject | SARS-CoV-2 | pt_BR |
Subject | COVID-19 | pt_BR |
Subject | Vaccine | pt_BR |
Subject | ATL | pt_BR |
Subject | HAM/TSP | pt_BR |
Subject | HTLV | pt_BR |